Several research studies indicate that polymer-modified CNTs can treat tumours by acting as immune adjuvants to promote the maturation of dendritic cells (DCs), the CD8+ T cell infiltration in TME, and the release of antitumour factors [230]. The gene discussed is CD8A; the disease is neoplasm.